Article Text

Download PDFPDF
Efficiency of tofacitinib in refractory interstitial lung disease among anti-MDA5 positive juvenile dermatomyositis patients

Statistics from Altmetric.com

Footnotes

  • Handling editor Josef S Smolen

  • YX and JZ contributed equally.

  • Contributors YX and JZ contribute the same in this study.YX,JZ and CFL designed the research study; YX wrotethe manuscript; JZ,JD, and WK collected the clinical data.SL and XT revised themanuscript. All authors read and approved the final manuscript.

    YX,JZ and CFL designed the research study; YX wrotethe manuscript; JZ,JD, and WK collected the clinical data.SL and XT revised themanuscript. All authors read and approved the final manuscript.

  • Funding This study was supported by the Capital's Fund's for Health Improvement and Research(CFH2022-2-2096) and National Regional Medical Center Opening Project(NRMC0110).

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.